公开(公告)号：US20230014839A1

公开(公告)日：2023-01-19

申请号：US17931633

申请日：2022-09-13

Applicant: Janssen Biotech, Inc.

Inventor： Ming-Chun Hsu ,  Shu Li ,  Bruce Randazzo ,  Kun Song ,  Yaowei Zhu

IPC: C07K16/24 ,  A61P17/06

Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.

公开(公告)号：US20220073603A1

公开(公告)日：2022-03-10

申请号：US17389533

申请日：2021-07-30

Applicant: Janssen Biotech, Inc.

Inventor： Ming-Chun Hsu ,  Shu Li ,  Bruce Randazzo ,  Kun Song ,  Yaowei Zhu

IPC: C07K16/24 ,  A61P17/06

Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.

公开(公告)号：US20240101662A1

公开(公告)日：2024-03-28

申请号：US18513931

申请日：2023-11-20

Applicant: Janssen Biotech, Inc.

Inventor： Ming-Chun Hsu ,  Shu Li ,  Bruce Randazzo ,  Kun Song ,  Yaowei Zhu

IPC: C07K16/24 ,  A61P17/06

CPC classification number: C07K16/244 ,  A61P17/06 ,  A61K2039/505

Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.

公开(公告)号：US20200331996A1

公开(公告)日：2020-10-22

申请号：US16819629

申请日：2020-03-16

Applicant: Janssen Biotech, Inc.

Inventor： Ming-Chun Hsu ,  Shu Li ,  Bruce Randazzo ,  Kun Song ,  Yaowei Zhu

IPC: C07K16/24 ,  A61P17/06

Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.